Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

9821	Companies
197090	Keywords
128169	Articles
104821	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 10/17/2024 at 14:35, 1 year 3 months ago

Xenetic Biosciences Partners with Tokyo Medical University for Cancer Research

Xenetic Biosciences Cancer Research Ewing Sarcoma DNase I Tokyo Medical University
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 3 months ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic partners with Tokyo Medical University to evaluate recombinant DNase I for Ewing sarcoma treatment in preclinical model. Agreement enhances DNase program development

Xenetic Ewing Sarcoma Tokyo Medical University Recombinant DNase I Preclinical Model
BRIEF

published on 09/11/2024 at 15:05, 1 year 4 months ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Xenetic Biosciences H.C. Wainwright Immune-oncology Investment Presentation Jim Parslow
BRIEF

published on 09/11/2024 at 15:05, 1 year 4 months ago

Xenetic Biosciences, Inc. présente sa 26e conférence annuelle sur l'investissement mondial organisée par HC Wainwright

Immuno-oncologie Biosciences Xénétiques HC Wainwright Jim Parslow Présentation D'investissement
PRESS RELEASE

published on 09/11/2024 at 15:00, 1 year 4 months ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences presented at H.C. Wainwright 26th Annual Global Investment Conference. The biopharmaceutical company focuses on immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Biopharmaceutical Immune-oncology JTC Team Cancers
BRIEF

published on 08/14/2024 at 14:05, 1 year 5 months ago

Xenetic Biosciences, Inc. publie ses résultats financiers du deuxième trimestre 2024 et fournit une mise à jour de ses activités

Résultats Financiers Biopharmaceutique Développement Clinique Programme D'oncologie Xénétique
BRIEF

published on 08/14/2024 at 14:05, 1 year 5 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Financial Results Clinical Development Biopharmaceutical Oncology Program Xenetic
PRESS RELEASE

published on 08/14/2024 at 14:00, 1 year 5 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash

Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF

published on 05/22/2024 at 23:05, 1 year 8 months ago

Xenetic Biosciences, Inc. annonce une transition de direction

Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
BRIEF

published on 05/22/2024 at 23:05, 1 year 8 months ago

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow

Accesswire

Published on 02/07/2026 at 01:00, 17 hours 21 minutes ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 19 hours 11 minutes ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 20 hours 20 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 2 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 4 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 16:35, 1 hour 46 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 2 hours 1 minute ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 22 hours 56 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 1 day ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.

Les Echos

Published on 02/06/2026 at 18:22, 23 hours 59 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 23 hours 59 minutes ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 2 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 2 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 10 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE